

Javier SÃ¡nchez RamÃ¡n

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8742968/publications.pdf>

Version: 2024-02-01

9
papers

101
citations

1684188

5
h-index

1588992

8
g-index

13
all docs

13
docs citations

13
times ranked

95
citing authors

#	ARTICLE	IF	CITATIONS
1	Specific humoral and cellular immune responses in cancer patients undergoing chronic immunization with a VEGF-based therapeutic vaccine. <i>Vaccine</i> , 2017, 35, 3582-3590.	3.8	30
2	Antigen dose escalation study of a VEGF-based therapeutic cancer vaccine in non human primates. <i>Vaccine</i> , 2012, 30, 368-377.	3.8	21
3	Specific active immunotherapy with the HEBERSaVax VEGF-based cancer vaccine: From bench to bedside. <i>Seminars in Oncology</i> , 2018, 45, 68-74.	2.2	11
4	Characteristics of the specific humoral response in patients with advanced solid tumors after active immunotherapy with a VEGF vaccine, at different antigen doses and using two distinct adjuvants. <i>BMC Immunology</i> , 2017, 18, 39.	2.2	10
5	Does VEGF-targeted active immunotherapy induce complete abrogation of platelet VEGF levels?. <i>BMC Research Notes</i> , 2019, 12, 323.	1.4	10
6	Indirect and competitive enzyme-linked immunosorbent assays for monitoring the humoral response against human VEGF. <i>Journal of Immunoassay and Immunochemistry</i> , 2016, 37, 636-658.	1.1	7
7	Evaluation of methodologies to determine the effect of specific active immunotherapy on VEGF levels in phase I clinical trial patients with advanced solid tumors. <i>Heliyon</i> , 2018, 4, e00906.	3.2	7
8	Specific humoral response in cancer patients treated with a VEGF-specific active immunotherapy procedure within a compassionate use program. <i>BMC Immunology</i> , 2020, 21, 12.	2.2	5
9	Potential mechanisms involved on how systemic IgG antibodies specific to vascular endothelial growth factor (VEGF) and induced by active immunotherapy decrease platelet derived free-VEGF. <i>Platelets</i> , 2022, , 1-5.	2.3	0